Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women

被引:250
|
作者
Mirza, Faryal S.
Padhi, I. Desmond [2 ]
Raisz, Lawrence G.
Lorenzo, Joseph A. [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Div Endocrinol, Farmington, CT 06030 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2010年 / 95卷 / 04期
关键词
BONE-FORMATION; PRIMARY HYPERPARATHYROIDISM; BMP ANTAGONIST; SOST; OSTEOPOROSIS; DENSITY; DISEASE; LIGAND; GENE; OSTEOBLASTS;
D O I
10.1210/jc.2009-2283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Sclerostin is a negative regulator of bone formation. Objective: The aim of the study was to compare serum sclerostin levels in premenopausal and postmenopausal women and evaluate its relationship to estrogen, TH, bone turnover, and bone mass. Design, Setting, and Participants: We conducted a cross-sectional observational study of healthy community-dwelling pre- and postmenopausal women. Intervention(s): There were no interventions. Main Outcome Measure(s): We compared serum sclerostin levels in pre- and postmenopausal women and correlated sclerostin levels with female sex hormones, calciotropic hormones, bone turnover markers, and bone mineral density. Results: Premenopausal women were 26.8 yr old, and postmenopausal women were 56.8 yr old. Postmenopausal women had lower values for estradiol (30 +/- 23 vs. 10 +/- 4 pg/ml; P < 0.001), estrone (61 +/- 24 vs. 29 +/- 10 pg/ml; P < 0.001), and free estrogen index (FEI) (6 +/- 4 vs. 3 +/- 2 pmol/nmol; P = 0.008) and significantly lower bone mineral density at all sites compared to premenopausal women, with no significant differences in levels of PTH, 25-hydroxy or 1,25-dihydroxy vitamin D levels. Postmenopausal women had significantly higher serum sclerostin levels (1.16 +/- 0.38 ng/ml vs. 0.48 +/- 0.15 ng/ml; P < 0.001). Because most of the premenopausal women were on oral contraceptives, subsequent analyses were limited to postmenopausal women. There were significant negative correlations between sclerostin and FEI and sclerostin and PTH in this group. Using multiple regression analysis, both FEI (beta = - 0.629; P = 0.002) and PTH (beta = -0.554; P = 0.004) were found to be independent predictors of sclerostin levels in postmenopausal women. Conclusions: Our findings suggest that serum sclerostin levels are regulated by both estrogens and PTH in postmenopausal women. These findings need to be explored further in larger prospective studies. (J Clin Endocrinol Metab 95: 1991-1997, 2010)
引用
收藏
页码:1991 / 1997
页数:7
相关论文
共 50 条
  • [1] Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
    Drake, Matthew T.
    Srinivasan, Bhuma
    Moedder, Ulrike I.
    Peterson, James M.
    McCready, Louise K.
    Riggs, B. Lawrence
    Dwyer, Denise
    Stolina, Marina
    Kostenuik, Paul
    Khosla, Sundeep
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11): : 5056 - 5062
  • [2] Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
    Cheng, Qun
    Wu, Xiaoxing
    Du, Yanping
    Hong, Wei
    Tang, Wenjing
    Li, Huilin
    Chen, Minmin
    Zheng, Songbai
    CLINICAL INTERVENTIONS IN AGING, 2018, 13 : 2367 - 2374
  • [3] Serum sclerostin levels following treatment with parathyroid hormone
    Polyzos, S. A.
    Anastasilakis, A. D.
    Terpos, E.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (04) : 280 - 280
  • [4] Serum sclerostin levels following treatment with parathyroid hormone
    S. A. Polyzos
    A. D. Anastasilakis
    E. Terpos
    Journal of Endocrinological Investigation, 2013, 36 : 280 - 280
  • [5] Circulating TGF-β1 levels are negatively correlated with sclerostin levels in early postmenopausal women
    Cheng, Qun
    Tang, Wenjing
    Sheu, Tzong-Jen
    Du, Yanping
    Gan, Jiemin
    Li, Huilin
    Hong, Wei
    Zhu, Xiaoying
    Xue, Sihong
    Zhang, Xuemei
    CLINICA CHIMICA ACTA, 2016, 455 : 87 - 92
  • [6] Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal Women
    Reppe, Sjur
    Noer, Agate
    Grimholt, Runa M.
    Halldorsson, Bjarni V.
    Medina-Gomez, Carolina
    Gautvik, Vigdis T.
    Olstad, Ole Kristoffer
    Berg, Jens Petter
    Datta, Harish
    Estrada, Karol
    Hofman, Albert
    Uitterlinden, Andre G.
    Rivadeneira, Fernando
    Lyle, Robert
    Collas, Philippe
    Gautvik, Kaare M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (02) : 249 - 256
  • [7] Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women
    Christodoulakos, G
    Lambrinoudaki, I
    Panoulis, C
    Rizos, D
    Coutoukos, J
    Creatsas, G
    FERTILITY AND STERILITY, 2003, 79 (02) : 455 - 456
  • [8] Serum sex hormone levels in postmenopausal women with hypertension
    Phillips, GB
    Jing, TY
    Laragh, JH
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (08) : 523 - 526
  • [9] Serum sex hormone levels in postmenopausal women with hypertension
    GB Phillips
    T-Y Jing
    JH Laragh
    Journal of Human Hypertension, 1997, 11 : 523 - 526
  • [10] Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone
    S. Piemonte
    E. Romagnoli
    C. Bratengeier
    W. Woloszczuk
    A. Tancredi
    J. Pepe
    C. Cipriani
    S. Minisola
    Journal of Endocrinological Investigation, 2012, 35 : 866 - 868